Galmed Pharmaceuticals (GLMD) Receivables - Other (2013 - 2025)

Galmed Pharmaceuticals' Receivables - Other history runs 13 years deep, the most recent figure standing at $347000.0 for Q4 2025.

• In Q4 2025, Receivables - Other fell 48.36% year-over-year to $347000.0; the TTM figure through Dec 2025 stood at $347000.0 (down 48.36% YoY), while the FY2025 annual figure was $347000.0, down 48.36% from the prior year.
• Receivables - Other was $347000.0 for Q4 2025 at Galmed Pharmaceuticals, down from $549000.0 in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.7 million in Q3 2021 to a low of $55000.0 in Q1 2023.
• Historically, Receivables - Other has averaged $620600.0 across 5 years, with a median of $518000.0 in 2021.
• The sharpest annual moves came in 2021 and 2024: Receivables - Other sank 99.86% in 2021, then surged 361.82% in 2024.
• A 5-year view of Receivables - Other shows it stood at $1.1 million in 2021, then retreated by 26.67% to $825000.0 in 2022, then tumbled by 41.82% to $480000.0 in 2023, then surged by 40.0% to $672000.0 in 2024, then tumbled by 48.36% to $347000.0 in 2025.
• The last three Receivables - Other figures came in at $347000.0 (Q4 2025), $549000.0 (Q3 2025), and $433000.0 (Q2 2025), per Business Quant data.